Patents by Inventor Mohammad Reza MASJEDIZADEH

Mohammad Reza MASJEDIZADEH has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Solid forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
    Patent number: 11708370
    Abstract: Solid forms of Compound (I): are disclosed. Pharmaceutical compositions comprising the same, methods of treating disorders and conditions mediated by BTK activity using the same, and methods for making Compound (I) and solid forms thereof are also disclosed.
    Type: Grant
    Filed: December 17, 2020
    Date of Patent: July 25, 2023
    Assignee: Principia Biopharma Inc.
    Inventors: Pasit Phiasivongsa, Katherine Chu, Jiang Zhu, Kolbot By, Mohammad Reza Masjedizadeh
  • Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4,4-dimethylpent-2-enenitrile
    Patent number: 11667641
    Abstract: Crystalline forms of Compound (I): are disclosed. Pharmaceutical compositions comprising the same, methods of inhibiting BTK using the same, and methods for making crystalline forms of Compound (I) are also disclosed.
    Type: Grant
    Filed: January 7, 2021
    Date of Patent: June 6, 2023
    Assignee: Principia Biopharma Inc.
    Inventors: Pasit Phiasivongsa, Jiang Zhu, Kolbot By, Mohammad Reza Masjedizadeh
  • Salts and Solid Form of a BTK Inhibitor
    Publication number: 20220370459
    Abstract: Disclosed herein are processes for preparing 2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile free base (compound (I)), salts of compound (I) and solid state form of said salts. Also disclosed herein are pharmaceutical compositions comprising such salts and solid state form thereof and methods of treating cancer, autoimmune, and inflammatory diseases using compound (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: May 24, 2022
    Publication date: November 24, 2022
    Applicant: Principia Biopharma, Inc.
    Inventors: Mohammad Reza Masjedizadeh, Steven Gourlay
  • Salts and solid form of a BTK inhibitor
    Patent number: 11369613
    Abstract: Disclosed herein are processes for preparing 2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile free base (compound (I)), salts of compound (I) and solid state form of said salts. Also disclosed herein are pharmaceutical compositions comprising such salts and solid state form thereof and methods of treating cancer, autoimmune, and inflammatory diseases using compound (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 5, 2020
    Date of Patent: June 28, 2022
    Assignee: Principia Biopharma Inc.
    Inventors: Mohammad Reza Masjedizadeh, Steven Gourlay
  • METHODS FOR SYNTHESIZING BETA-HOMOAMINO ACIDS
    Publication number: 20220185846
    Abstract: Methods of making ?-homoamino acids as intermediate for synthesis of peptide monmer and dimer ?4?7-antagonists are disclosed. The disclosed methods include solid phase and solution phase methods.
    Type: Application
    Filed: March 27, 2020
    Publication date: June 16, 2022
    Inventors: Suresh Kumar MANTHATI, Ashok BHANDARI, Mohammad Reza MASJEDIZADEH
  • CRYSTALLINE FORMS OF 2-[3-[4-AMINO-3-(2-FLUORO-4-PHENOXY-PHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-1-YL]PIPERIDINE-1-CARBONYL]-4,4-DIMETHYLPENT-2-ENENITRILE
    Publication number: 20210206772
    Abstract: Crystalline forms of Compound (I): are disclosed. Pharmaceutical compositions comprising the same, methods of inhibiting BTK using the same, and methods for making crystalline forms of Compound (I) are also disclosed.
    Type: Application
    Filed: January 7, 2021
    Publication date: July 8, 2021
    Inventors: Pasit Phiasivongsa, Jiang Zhu, Kolbot By, Mohammad Reza Masjedizadeh
  • SOLID FORMS OF 2-[3-[4-AMINO-3-(2-FLUORO-4-PHENOXY-PHENYL)PYRAZOLO[3,4-D]PYRIMIDIN-1-YL]PIPERIDINE-1-CARBONYL]-4-METHYL-4-[4-(OXETAN-3-YL)PIPERAZIN-1-YL]PENT-2-ENENITRILE
    Publication number: 20210198264
    Abstract: Solid forms of Compound (I): are disclosed. Pharmaceutical compositions comprising the same, methods of treating disorders and conditions mediated by BTK activity using the same, and methods for making Compound (I) and solid forms thereof are also disclosed.
    Type: Application
    Filed: December 17, 2020
    Publication date: July 1, 2021
    Inventors: Pasit Phiasivongsa, Katherine Chu, Jiang Zhu, Kolbot By, Mohammad Reza Masjedizadeh
  • SALTS AND SOLID FORM OF A BTK INHIBITOR
    Publication number: 20210015821
    Abstract: Disclosed herein are processes for preparing 2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile free base (compound (I)), salts of compound (I) and solid state form of said salts. Also disclosed herein are pharmaceutical compositions comprising such salts and solid state form thereof and methods of treating cancer, autoimmune, and inflammatory diseases using compound (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 5, 2020
    Publication date: January 21, 2021
    Applicant: PRINCIPIA BIOPHARMA INC.
    Inventors: Mohammad Reza MASJEDIZADEH, Steven Gourlay
  • Salts and solid form of a BTK inhibitor
    Patent number: 10828307
    Abstract: Disclosed herein are processes for preparing 2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile free base (compound (I)), salts of compound (I) and solid state form of said salts. Also disclosed herein are pharmaceutical compositions comprising such salts and solid state form thereof and methods of treating cancer, autoimmune, and inflammatory diseases using compound (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 8, 2019
    Date of Patent: November 10, 2020
    Assignee: Principia Biopharma Inc.
    Inventors: Mohammad Reza Masjedizadeh, Steven Gourlay
  • SALTS AND SOLID FORM OF A BTK INHIBITOR
    Publication number: 20200038405
    Abstract: Disclosed herein are processes for preparing 2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile free base (compound (I)), salts of compound (I) and solid state form of said salts. Also disclosed herein are pharmaceutical compositions comprising such salts and solid state form thereof and methods of treating cancer, autoimmune, and inflammatory diseases using compound (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 8, 2019
    Publication date: February 6, 2020
    Applicant: PRINCIPIA BIOPHARMA INC.
    Inventors: Mohammad Reza MASJEDIZADEH, Steven GOURLAY
  • Salts and solid form of a BTK inhibitor
    Patent number: 10456403
    Abstract: Disclosed herein are processes for preparing 2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile free base (compound (I)), salts of compound (I) and solid state form of said salts. Also disclosed herein are pharmaceutical compositions comprising such salts and solid state form thereof and methods of treating cancer, autoimmune, and inflammatory diseases using compound (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 29, 2018
    Date of Patent: October 29, 2019
    Assignee: PRINCIPIA BIOPHARMA INC.
    Inventors: Mohammad Reza Masjedizadeh, Steven Gourlay
  • SALTS AND SOLID FORM OF A BTK INHIBITOR
    Publication number: 20190076435
    Abstract: Disclosed herein are processes for preparing 2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]pyiperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile free base (compound (I)), salts of compound (I) and solid state form of said salts. Also disclosed herein are pharmaceutical compositions comprising such salts and solid state form thereof and methods of treating cancer, autoimmune, and inflammatory diseases using compound (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 29, 2018
    Publication date: March 14, 2019
    Applicant: PRINCIPIA BIOPHARMA INC.
    Inventors: Mohammad Reza MASJEDIZADEH, Steven GOURLAY
  • Salts and solid form of a BTK inhibitor
    Patent number: 10092569
    Abstract: Disclosed herein are processes for preparing 2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile free base (compound (I)), salts of compound (I) and solid state form of said salts. Also disclosed herein are pharmaceutical compositions comprising such salts and solid state form thereof and methods of treating cancer, autoimmune, and inflammatory diseases using compound (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: October 9, 2018
    Assignee: PRINCIPIA BIOPHARMA INC.
    Inventors: Mohammad Reza Masjedizadeh, Steven Gourlay
  • COMPOSITIONS FOR ILEO-JEJUNAL DRUG DELIVERY
    Publication number: 20180193274
    Abstract: The current invention affords new formulations which deliver reversible and irreversible covalent kinase inhibitors, in particular BTK inhibitors, into the small intestine and specifically into the ileum and jejunum of the small intestine.
    Type: Application
    Filed: December 23, 2015
    Publication date: July 12, 2018
    Inventors: Philip A. NUNN, Bret BERNER, Mohammad Reza MASJEDIZADEH
  • SITE SPECIFIC DOSING OF A BTK INHIBITOR
    Publication number: 20180015088
    Abstract: Disclosed herein are formulations and methods of site specific administration of Compound (I) or a pharmaceutically acceptable salt thereof. Compound (I) is a potent BTK inhibitor and hence can be useful for the treatment of diseases such as cancer, autoimmune, and inflammatory diseases.
    Type: Application
    Filed: December 23, 2015
    Publication date: January 18, 2018
    Inventors: Philip NUNN, Bret BERNER, Mohammad Reza MASJEDIZADEH
  • SALTS AND SOLID FORM OF A BTK INHIBITOR
    Publication number: 20170065591
    Abstract: Disclosed herein are processes for preparing 2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile free base (compound (I)), salts of compound (I) and solid state form of said salts. Also disclosed herein are pharmaceutical compositions comprising such salts and solid state form thereof and methods of treating cancer, autoimmune, and inflammatory diseases using compound (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: February 20, 2015
    Publication date: March 9, 2017
    Inventors: Mohammad Reza MASJEDIZADEH, Steven GOURLAY